Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Down 14.2% in December

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) was the recipient of a significant decline in short interest in December. As of December 31st, there was short interest totalling 1,030,000 shares, a decline of 14.2% from the December 15th total of 1,200,000 shares. Approximately 1.8% of the company’s stock are short sold. Based on an average trading volume of 131,000 shares, the days-to-cover ratio is currently 7.9 days.

Nautilus Biotechnology Stock Performance

NAUT traded up $0.03 on Friday, hitting $1.93. The company had a trading volume of 77,540 shares, compared to its average volume of 149,773. The stock has a fifty day moving average price of $2.02 and a 200-day moving average price of $2.42. Nautilus Biotechnology has a 12-month low of $1.61 and a 12-month high of $3.12. The stock has a market capitalization of $242.34 million, a price-to-earnings ratio of -3.45 and a beta of 1.20.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its quarterly earnings results on Tuesday, October 29th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.04. During the same period in the previous year, the business posted ($0.13) EPS. Analysts forecast that Nautilus Biotechnology will post -0.57 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group downgraded Nautilus Biotechnology from a “neutral” rating to a “sell” rating and decreased their price objective for the company from $2.25 to $1.75 in a report on Thursday, December 5th.

Institutional Investors Weigh In On Nautilus Biotechnology

A number of large investors have recently modified their holdings of the business. SG Americas Securities LLC grew its stake in shares of Nautilus Biotechnology by 56.3% during the fourth quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock worth $46,000 after acquiring an additional 9,904 shares during the last quarter. Barclays PLC grew its stake in shares of Nautilus Biotechnology by 79.6% during the third quarter. Barclays PLC now owns 106,174 shares of the company’s stock worth $303,000 after acquiring an additional 47,059 shares during the last quarter. Wexford Capital LP lifted its holdings in shares of Nautilus Biotechnology by 9.6% during the third quarter. Wexford Capital LP now owns 228,350 shares of the company’s stock worth $651,000 after purchasing an additional 20,000 shares during the period. MetLife Investment Management LLC acquired a new stake in shares of Nautilus Biotechnology during the third quarter worth about $87,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Nautilus Biotechnology during the third quarter worth about $67,000. Hedge funds and other institutional investors own 50.71% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.